HUTCHMED (NASDAQ:HCM) Stock Price Up 6.6% – Should You Buy?

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) traded up 6.6% during mid-day trading on Thursday . The company traded as high as $11.64 and last traded at $11.4960. 48,063 shares traded hands during trading, an increase of 16% from the average daily volume of 41,289 shares. The stock had previously closed at $10.78.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HCM. Wall Street Zen cut HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Morgan Stanley set a $13.60 target price on HUTCHMED in a research note on Thursday, May 28th. Bank of America decreased their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 10th. Finally, Weiss Ratings lowered shares of HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, HUTCHMED has an average rating of “Hold” and an average price target of $16.80.

HUTCHMED Stock Performance

The stock’s 50-day moving average price is $11.69 and its 200 day moving average price is $13.56. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. increased its holdings in HUTCHMED by 131.5% during the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after purchasing an additional 4,378 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares during the period. Bank of America Corp DE lifted its holdings in shares of HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after buying an additional 3,035 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of HUTCHMED by 34.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after buying an additional 5,538 shares during the period. Finally, Janney Montgomery Scott LLC bought a new position in shares of HUTCHMED during the 1st quarter worth $365,000. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.